In this video, Allen C. Gao, MD, PhD, discusses the background and findings of the study, “Resistance to olaparib is dependent on re-emergence from G2/M arrested senescence,” presented at the 2021 American Urological Association Annual Meeting. Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.